ADAGE CAPITAL PARTNERS GP, L.L.C. Goes on Buying Spree in 2nd Quarter

Author's Avatar
insider
Aug 15, 2022
Article's Main Image

ADAGE CAPITAL PARTNERS GP, L.L.C. recently filed their 13F report for the second quarter of 2022, which ended on 2022-06-30.

The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.

200 Clarendon Street, 52nd Floor Boston, MA 02116

As of the latest 13F report, the guru’s equity portfolio contained 1073 stocks valued at a total of $43.52Bil. The top holdings were AAPL(5.00%), MSFT(4.68%), and AMZN(2.22%).

According to GuruFocus data, these were ADAGE CAPITAL PARTNERS GP, L.L.C.’s top five trades of the quarter.

89bio Inc


During the quarter, ADAGE CAPITAL PARTNERS GP, L.L.C. bought 1,590,000 shares of NAS:ETNB for a total holding of 2,690,000. The trade had a 0.01% impact on the equity portfolio. During the quarter, the stock traded for an average price of $3.55.

On 08/15/2022, 89bio Inc traded for a price of $4.78 per share and a market cap of $184.01Mil. The stock has returned -74.46% over the past year.

GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 1 out of 10.

In terms of valuation, 89bio Inc has a price-book ratio of 0.93 and a EV-to-Ebitda ratio of -0.65.

East Resources Acquisition Co


The guru established a new position worth 2,348,214 shares in NAS:ERESU, giving the stock a 0.04% weight in the equity portfolio. Shares traded for an average price of $10.05 during the quarter.

On 08/15/2022, East Resources Acquisition Co traded for a price of $10.13 per share and a market cap of $0.00Mil. The stock has returned 0.10% over the past year.

GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 1 out of 10.

In terms of valuation, East Resources Acquisition Co has a price-book ratio of 1.32.

Annexon Inc


During the quarter, ADAGE CAPITAL PARTNERS GP, L.L.C. bought 3,228,931 shares of NAS:ANNX for a total holding of 4,184,561. The trade had a 0.03% impact on the equity portfolio. During the quarter, the stock traded for an average price of $3.97.

On 08/15/2022, Annexon Inc traded for a price of $6.1489 per share and a market cap of $292.37Mil. The stock has returned -68.35% over the past year.

GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 1 out of 10.

In terms of valuation, Annexon Inc has a price-book ratio of 1.73 and a EV-to-Ebitda ratio of -1.01.

Newpark Resources Inc


During the quarter, ADAGE CAPITAL PARTNERS GP, L.L.C. bought 300,000 shares of NYSE:NR for a total holding of 4,759,137. The trade had a 0% impact on the equity portfolio. During the quarter, the stock traded for an average price of $3.04.

On 08/15/2022, Newpark Resources Inc traded for a price of $2.735 per share and a market cap of $256.62Mil. The stock has returned 17.67% over the past year.

GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 5 out of 10.

In terms of valuation, Newpark Resources Inc has a price-book ratio of 0.58, a EV-to-Ebitda ratio of 13.12 and a price-sales ratio of 0.34.

The price-to-GF Value ratio is 0.70, earning the stock a GF Value rank of 10.

Biohaven Pharmaceutical Holding Co Ltd


During the quarter, ADAGE CAPITAL PARTNERS GP, L.L.C. bought 2,849,092 shares of NYSE:BHVN for a total holding of 3,039,092. The trade had a 0.96% impact on the equity portfolio. During the quarter, the stock traded for an average price of $127.59.

On 08/15/2022, Biohaven Pharmaceutical Holding Co Ltd traded for a price of $147.97 per share and a market cap of $10.58Bil. The stock has returned 26.89% over the past year.

GuruFocus gives the company a financial strength rating of 3 out of 10 and a profitability rating of 1 out of 10.

In terms of valuation, Biohaven Pharmaceutical Holding Co Ltd has a EV-to-Ebitda ratio of -14.86 and a price-sales ratio of 11.82.


Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.

Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!

This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.

Rating:
0 / 5 (0 votes)
Author's Avatar
WRITTEN BY

Request A Demo

Learn more about GuruFocus' key features, including All-In-One Screener, backtesting, 30-year financial, stock summary page, guru trades, insider trades, excel Add-in, google sheets and much more.

GuruFocus Screeners

Related Articles